Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zinlirvimab - Gilead Sciences

Next Previous
Drug Profile

Zinlirvimab - Gilead Sciences

Alternative Names: 10 1074; 10-1074-LS; 10-1074-LS-J; Anti-HIV-1-neutralising-antibody; GS-2872

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rockefeller University
  • Developer Aarhus Universitetshospital; Gilead Sciences; National Institute of Allergy and Infectious Diseases; Rockefeller University; University of California at San Francisco; University of Cologne
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV envelope protein gp120 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 02 Sep 2026 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences suspends the phase-I/II trial in HIV-1 infections (Combination therapy, Treatment-experienced) in US and Brazil (NCT06071767)
  • 14 Jul 2026 Phase-III clinical trials in HIV-1 infections (Combination therapy, Treatment-experienced) in USA (IV) (NCT07682961)
  • 06 Jul 2026 Gilead Sciences plans a phase III trial for HIV-1 infections (Treatment-experienced, Combination therapy) in July 2027 (IV) (NCT07682961) (CTIS-2025-524335-39)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top